Working… Menu

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01128439
Recruitment Status : Completed
First Posted : May 21, 2010
Last Update Posted : December 4, 2018
Kaiser Permanente
Information provided by (Responsible Party):

Brief Summary:
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Condition or disease Intervention/treatment
Invasive Pneumococcal Disease Other: No intervention

Detailed Description:
No sampling as no subjects are enrolled

Layout table for study information
Study Type : Observational
Actual Enrollment : 1 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use
Study Start Date : July 2010
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
1 Other: No intervention
No intervention

Primary Outcome Measures :
  1. Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13. [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary Care Clinic

Inclusion Criteria:

  • Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01128439

Layout table for location information
United States, California
Kaiser Permanente Vaccine Study Center
Oakland, California, United States, 94612
Sponsors and Collaborators
Kaiser Permanente
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT01128439    
Other Study ID Numbers: 6096A1-4005
B1851042 ( Other Identifier: Alias Study Number )
First Posted: May 21, 2010    Key Record Dates
Last Update Posted: December 4, 2018
Last Verified: November 2018
Keywords provided by Pfizer:
Pneumococcal conjugate vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumococcal Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections